Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. May 10, 2014; 5(2): 93-102
Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.93
Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.93
Relationship between head and neck cancer therapy and some genetic endpoints
Eliana Maria Minicucci, Departamento de Dermatologia e Radioterapia, Faculdade de Medicina de Botucatu, Univ. Estadual Paulista, UNESP, Botucatu, SP 18618-000, Brazil
Glenda Nicioli da Silva, Departamento de Análises Clínicas, Escola de Farmácia, Univ. Federal de Ouro Preto, UFOP, Ouro Preto, 35400-000, Brazil
Daisy Maria Fávero Salvadori, Departamento de Patologia, Faculdade de Medicina de Botucatu, Univ. Estadual Paulista, UNESP, Botucatu, SP 18618-000, Brazil
Author contributions: Minicucci EM and da Silva GN collected the literature and drafted the first version of the manuscript; Salvadori DMF did a critical reading of the manuscript and included additional literature.
Correspondence to: Daisy Maria Fávero Salvadori, PhD, Departamento de Patologia, Faculdade de Medicina de Botucatu, Univ. Estadual Paulista, UNESP, Botucatu Distrito de Rubião Júnior, s/nº, Botucatu, SP 18618-000, Brazil. dfavero@fmb.unesp.br
Telephone: +55-14-38807210 Fax: +55-14-38807210
Received: December 17, 2013
Revised: February 22, 2014
Accepted: March 13, 2014
Published online: May 10, 2014
Revised: February 22, 2014
Accepted: March 13, 2014
Published online: May 10, 2014
Core Tip
Core tip: The main therapies for head and neck cancer (HNC) are surgery, radiotherapy (RT) and chemotherapy. Considering that both RT and chemotherapeutical drugs can interact with the DNA, one of the important, late-occurring complications is a therapy-related secondary tumor resulting from the genotoxic effects of the therapy on the healthy cells. This review presents an update of the toxicogenetic and toxicogenomic effects of HNC treatments, highlighting the main mechanisms evolved in the secondary damage caused by RT and chemotherapies.